PURPOSE: To compare the efficiency and efficacy of two starting doses of recombinant FSH (follitropin-beta, Puregon) in women undergoing IVF treatment. METHODS: This prospective, randomized, double-blind, multicentric (N = 6) study included 192 women undergoing IVF using the long protocol ofGnRH agonist who received either 100 IU or 200 IU of r-FSH per day. Gonadotropin dose adjustment was allowed after day 4 of stimulation. RESULTS: The average (SD) number of oocytes retrieved was 10.9 (5.4) and 12.2 (5.6) in the 100 IU and 200 IU group respectively (p = 0.067). The total doses of Puregon administered were 1887 IU and 2559 IU in the 100 IU and 200 IU group respectively. The number of transferable embryos, and the rates of pregnancies, cancelled cycles, miscarriages and adverse events including OHSS were comparable between the two groups. CONCLUSIONS: Women undergoing IVF have similar outcomes whether recombinant FSH is commenced in a dose of 100 IU or 200 IU for the first 4 days of stimulation.
RCT Entities:
PURPOSE: To compare the efficiency and efficacy of two starting doses of recombinant FSH (follitropin-beta, Puregon) in women undergoing IVF treatment. METHODS: This prospective, randomized, double-blind, multicentric (N = 6) study included 192 women undergoing IVF using the long protocol of GnRH agonist who received either 100 IU or 200 IU of r-FSH per day. Gonadotropin dose adjustment was allowed after day 4 of stimulation. RESULTS: The average (SD) number of oocytes retrieved was 10.9 (5.4) and 12.2 (5.6) in the 100 IU and 200 IU group respectively (p = 0.067). The total doses of Puregon administered were 1887 IU and 2559 IU in the 100 IU and 200 IU group respectively. The number of transferable embryos, and the rates of pregnancies, cancelled cycles, miscarriages and adverse events including OHSS were comparable between the two groups. CONCLUSIONS:Women undergoing IVF have similar outcomes whether recombinant FSH is commenced in a dose of 100 IU or 200 IU for the first 4 days of stimulation.
Authors: H J Out; I David; R Ron-El; S Friedler; E Shalev; J Geslevich; J Dor; A Shulman; Z Ben-Rafael; B Fisch; M Dirnfeld Journal: Hum Reprod Date: 2001-06 Impact factor: 6.918
Authors: H J Out; D D Braat; B M Lintsen; T Gurgan; O Bukulmez; O Gökmen; G Keles; P Caballero; J M González; F Fábregues; J Balasch; R Roulier Journal: Hum Reprod Date: 2000-01 Impact factor: 6.918
Authors: Sarah F Lensen; Jack Wilkinson; Jori A Leijdekkers; Antonio La Marca; Ben Willem J Mol; Jane Marjoribanks; Helen Torrance; Frank J Broekmans Journal: Cochrane Database Syst Rev Date: 2018-02-01
Authors: Mary C Mahony; Brooke Hayward; Gilbert L Mottla; Kevin S Richter; Stephanie Beall; G David Ball; Thomas D'Hooghe Journal: Front Endocrinol (Lausanne) Date: 2021-12-09 Impact factor: 5.555